Verona Pharma plc - American Depositary Share (VRNA) Social Stream
Verona Pharma plc (VRNA) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Verona Pharma plc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
VRNA's average price target has moved up $4.35 over the prior 17 months.
VRNA reports an average of 276.14% for its upside potential over the past 117 days.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
VRNA Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 120 days, VRNA's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for VRNA as an investment opportunity.
- In terms of how Verona Pharma plc fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 372.98% of that group.
- In the context of all US stocks, Verona Pharma plc's number of analysts covering the stock is greater than 94.12% of them.
- In the context of all US stocks, Verona Pharma plc's average analyst price target is higher than 97.06% of them.
- In terms of how Verona Pharma plc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -23.44% of that group.
What is the outlook for VRNA? Use POWR Ratings for clearer insight into price direction.